C-reactive Protein Testing Market Analysis

C-reactive Protein Testing Market Analysis 

To get key market trends

  Download Free Sample

Based on product, the market is categorized into instruments, kits and reagents. The kits and reagents segment dominated the market with the revenue of 2 billion in 2023.
 

• Kits and reagents are versatile and can be used with various instruments and platforms, making them suitable for different types of CRP assays, such as chemiluminescence immunoassay (CLIA), enzyme-linked immunosorbent assay (ELISA), and immunoturbidimetric assay. This adaptability increases their utilization across diverse clinical settings.
   
• Moreover, many CRP testing kits are designed to be user-friendly and provide rapid results, which is crucial in clinical settings where timely decision-making is essential. The convenience and efficiency of these kits contribute to their preference over more complex and time-consuming methods.
    

Based on assay type, the C-reactive protein testing market is categorized into chemiluminescence immunoassay (CLIA), enzyme-linked immunosorbent assay (ELISA), immunoturbidimetric assay, and other assay types. The immunoturbidimetric assay segment anticipated to dominate the market with the revenue of 1.6 billion during forecast period.
 

• Immunoturbidimetric assays are more affordable compared to other assay types like chemiluminescence immunoassay (CLIA) and enzyme-linked immunosorbent assay (ELISA). This cost-effectiveness makes them an attractive option for a wide range of healthcare providers, including smaller clinics and laboratories with limited budgets.
   
• Additionally, these assays are known for their rapid processing time and efficiency. They can deliver quick results, which is crucial in clinical settings where timely decision-making is necessary. The faster turnaround time helps in promptly diagnosing and managing inflammatory conditions, hence contributes to their segmental growth.
   

Based on detection range, the C-reactive protein testing market is categorized into high-sensitivity CRP (Hs-CRP), and standard CRP. The standard CRP segment dominated the market by obtaining market share of around 54% in 2023.
 

• Standard CRP tests are widely used across a broad range of clinical applications. They are employed in the diagnosis and monitoring of various inflammatory and infectious diseases, as well as chronic conditions. This versatility makes them a staple in routine clinical practice.
   
• Moreover, Hs-CRP tests are necessary for detecting low levels of CRP in cardiovascular risk assessment, standard CRP tests are adequate for diagnosing and monitoring acute infections, inflammatory diseases, and other conditions where higher levels of CRP are present, hence contributes to its segmental growth.  
   

Based on application, the C-reactive protein testing market is categorized into cardiovascular diseases, infectious diseases, chronic inflammatory diseases, and other applications. The cardiovascular diseases segment anticipated to dominate the market with the revenue of 1.7 billion during forecast period.
 

• Cardiovascular diseases are among the leading causes of morbidity and mortality worldwide, affecting a large patient population. The high prevalence of cardiovascular conditions generates substantial demand for CRP testing, both for initial risk assessment and ongoing monitoring.
   
• Additionally, CRP testing has become integrated into routine cardiac care, particularly in the management of patients with existing cardiovascular diseases. Regular monitoring of CRP levels helps in assessing the efficacy of treatments and guiding therapeutic decisions, contributing to its dominance in this segment.
   

Based on end-use, the C-reactive protein testing market is categorized into hospitals and clinics, diagnostic laboratories, and other end-users. The hospitals and clinics segment dominated the market with a revenue of around USD 1.6 billion in 2023.
 

• In hospitals and clinics, CRP testing is often performed to support immediate clinical decision-making. Rapid results from CRP tests can help physicians quickly diagnose and manage conditions such as infections, inflammatory diseases, and cardiovascular events, which are critical in acute care settings.
   
• Moreover, hospitals and clinics serve a multidisciplinary patient population, including those in departments like internal medicine, cardiology, infectious diseases, and rheumatology. The cross-departmental use of CRP testing further amplifies its demand for these facilities.
   

North America C-reactive protein testing market accounted for USD 1.2 billion in revenue in 2023 and is predicted to witness substantial market growth over the analysis timeline.
 

• North America has a high prevalence of chronic diseases such as cardiovascular diseases and diabetes. This increased incidence drives the demand for C-reactive protein (CRP) testing, as CRP levels are commonly monitored to assess inflammation related to these conditions.
   
• Additionally, the presence of advanced healthcare facilities and widespread access to diagnostic technologies in North America supports the growth of the CRP testing market. High adoption rates of innovative diagnostic tools and a focus on early disease detection contribute to increased CRP test utilization.
   

The U.S. C-reactive protein testing market is anticipated to reach USD 1.4 billion by 2032, driven by numerous factors.
 

• There is a growing emphasis on preventive healthcare in the U.S., which drives the demand for CRP testing as part of routine health check-ups and preventive screenings. Healthcare policies promoting preventive measures and early diagnosis further bolster market growth.
   
• Additionally, the awareness and education surrounding inflammatory diseases and their links to various health conditions have increased. This heightened awareness encourages both patients and healthcare providers to utilize CRP testing for better management and monitoring of inflammatory conditions.
   

The C-reactive protein testing market in UK is expected to experience significant and promising growth from 2024 to 2032.
 

• The UK's healthcare system, guided by the National Health Service (NHS), incorporates regular screening and monitoring of inflammatory markers like CRP. NHS guidelines and recommendations for managing chronic diseases contribute to the steady demand for CRP testing.
   
• Additionally, the increasing elderly population in the UK, who are more susceptible to inflammatory diseases and chronic conditions, drives the need for CRP testing. As the aging population grows, so does the requirement for diagnostic tools to monitor inflammation and related health issues.
   

Japan C-reactive protein testing market is anticipated to witness lucrative growth between 2024 – 2032.
 

• The country's focus on technological innovation and its strong emphasis on healthcare research and development contribute to the growth of the CRP testing market. Advanced diagnostic technologies and integration of CRP testing into routine clinical practices drive market expansion.
   
• Additionally, the Japanese government’s health initiatives and comprehensive screening programs aim to address chronic diseases and promote early detection. These programs often include CRP testing to monitor inflammation and manage health conditions, thus supporting market growth.